B. Riley Adjusts Price Target on MiNK Therapeutics to $50 From $43, Maintains Buy Rating

B. Riley has raised its price target on MiNK Therapeutics, Inc. (Ticker: INKT) from $43 to $50 while maintaining a 'Buy' rating on the company's shares. This adjustment is based on the firm's assessment of MiNK Therapeutics, which focuses on allogeneic iNKT cell therapies.